Tobacco Trends Improve; Altria Still Undervalued
We are modestly raising our forecasts for this year, but retain our $54 fair value estimate and wide moat rating.
Altria (MO) reported a resilient second-quarter performance, with revenue slightly above our expectations, although smokeless margins were a little light. Underlying trends in the U.S. cigarette industry improved during the lockdown period, and we expect some degree of mean reversion next year. We are modestly raising our forecasts for this year, but retain our $54 fair value estimate and wide moat rating. Altria, like the rest of the tobacco group, remains undervalued relative to our estimate of its intrinsic value.
Reported cigarette shipment volume was down by almost 9% in the second quarter, offset by 6% pricing. After adjusting for inventory trade movements, however, the underlying smokeable volumes fell by just 2%, a significant improvement from the 4% to 5% decline of recent years. We think this is for two reasons. The first is the temporary effect of smokers staying at home and having more time, social freedom and discretionary income to spend on smoking. The second is the structural effect of nicotine consumers switching back to smoking from vaping, following the clampdown on flavored nicotine liquids by the Food and Drug Administration, or FDA. While it is difficult to quantify the impact of these factors, and management has refrained from reinstating medium-term guidance, we believe our medium-term estimate of a 3.5% annual volume decline in a normalized environment remains realistic, and assumes a material contraction in the vaping category.
The top line in the smokeless division was also respectable, with revenue up 10% on adjusted volume growth of 0.5%. This was driven by industry growth, however, and Altria again lost share, most likely to the emerging category of oral nicotine pouches. Altria's distribution capabilities, one source of its wide economic moat, should allow it to grow share in this category with on! Smokeless margins were slightly disappointing, down 120 basis points year over year.
|Morningstar Premium Members gain exclusive access to our full analyst reports, including fair value estimates, bull and bear breakdowns, and risk analyses. Not a Premium Member? Get this and other reports immediately when you try Morningstar Premium free for 14 days.|
Philip Gorham does not own (actual or beneficial) shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
We’d like to share more about how we work and what drives our day-to-day business.
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.
How we use your information depends on the product and service that you use and your relationship with us. We may use it to:
To learn more about how we handle and protect your data, visit our privacy center.
Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.
To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.
Read our editorial policy to learn more about our process.